4Dcell’s Post

If you're looking for high-quality, functional sensory neurons to fuel your in vitro models, we can help. We've spent the last 10 years developing our manufacturing capabilities to become the first choice for consistent, functionally relevant iPSC-derived sensory neurons to power robust cosmetic toxicology and pain/touch models. Studying neurite degradation and neuronal activity requires cells that demonstrate robust neurite outgrowth and key functionality. In this excerpt from our Sensory Neurons iPSC tech help clinic, Axol Strategic Partnership Manager Stuart Prime presents data from two key assays using axoCells™ Sensory Neurons to investigate drug response: • Investigating neurite degradation in response to a chemotherapy drug • Using fluorescent reporters in a 96-well plate format to measure general neuronal activity including burst rate If you have a drug you want to investigate, we can do this here at operations@axolbio.com Click here to watch the full webinar: https://hubs.la/Q02JbZ-N0 #iPSCs #SensoryNeurons #DrugDiscovery #CosmeticToxicology #PainResearch

If you're looking for high-quality, functional sensory neurons to fuel your in vitro models, we can help. We've spent the last 10 years developing our manufacturing capabilities to become the first choice for consistent, functionally relevant iPSC-derived sensory neurons to power robust cosmetic toxicology and pain/touch models. Studying neurite degradation and neuronal activity requires cells that demonstrate robust neurite outgrowth and key functionality. In this excerpt from our Sensory Neurons iPSC tech help clinic, Axol Strategic Partnership Manager Stuart Prime presents data from two key assays using axoCells™ Sensory Neurons to investigate drug response: • Investigating neurite degradation in response to a chemotherapy drug • Using fluorescent reporters in a 96-well plate format to measure general neuronal activity including burst rate If you have a drug you want to investigate, we can do this here at operations@axolbio.com Click here to watch the full webinar: https://hubs.la/Q02JbZ-M0 #iPSCs #SensoryNeurons #DrugDiscovery #CosmeticToxicology #PainResearch

We're heading to SOT next week! From the 10th-14th March, we'll be in Salt Lake City attending the Society of Toxicology 63rd Annual Meeting and ToxExpo. Cardiotoxicity and neurotoxicity are two key challenges for drug discovery, hence their inclusion in the "core battery" of safety pharmacology tests. We're excited to discuss our work unlocking iPSC technology for in vitro toxicity models that are fueled by consistent, functionally relevant human iPSC-derived cells. Our key safety pharmacology areas include: • Chamber-specific cardiotoxicity models • Sensory and cosmetic toxicology • CNS toxicity and epilepsy If you're interested in learning more, we've got some exciting announcements in the next few days! To get the ball rolling, take a look at this application note on the external validation of our axoCells™ ventricular cardiomyocytes against the CiPA compound panel: https://hubs.la/Q02mQLXF0 #iPSCs #SOT #cardiotoxicity #neurotoxicity #CiPA #DrugDiscovery

📢Preventing, Predicting, and Mitigating ADC Toxicities! The 2nd ADC Toxicity Summit returns as the only conference bringing together 80+ experts in toxicology, pathology, translational sciences and more, to exclusively address challenges in minimizing ADC toxicity - https://ter.li/xa0lrc As toxicities continue to pose the most significant challenge in the progression of antibody-drug conjugates, join your peers to unlock first-hand insights into how to improve prediction and translation of ADC toxicities to drive more tolerable ADCs successfully into and through clinical development. Discover how to tackle ADC toxicities using in vivo models, enhancing the therapeutic index of ADCs, improving predictability, and much more – find out more here: https://ter.li/xa0lrc Don’t miss out on this unparalleled opportunity to collaborate with industry leaders to navigate the prevention, prediction, and mitigation of ADC toxicities, and make meaningful strides forward in developing safer ADCs. Register before midnight Friday, May 17 to save $850 – https://ter.li/lce30w

We're heading to SOT next week! From the 10th-14th March, we'll be in Salt Lake City attending the Society of Toxicology 63rd Annual Meeting and ToxExpo. Cardiotoxicity and neurotoxicity are two key challenges for drug discovery, hence their inclusion in the "core battery" of safety pharmacology tests. We're excited to discuss our work unlocking iPSC technology for in vitro toxicity models that are fueled by consistent, functionally relevant human iPSC-derived cells. Our key safety pharmacology areas include: • Chamber-specific cardiotoxicity models • Sensory and cosmetic toxicology • CNS toxicity and epilepsy If you're interested in learning more, we've got some exciting announcements in the next few days! To get the ball rolling, take a look at this application note on the external validation of our axoCells™ ventricular cardiomyocytes against the CiPA compound panel: https://hubs.la/Q02mQP3c0 #iPSCs #SOT #cardiotoxicity #neurotoxicity #CiPA #DrugDiscovery

🎥 Check out the video to explore how Creatio conducts some steps of the immunofluorescence labelling in the Brain on a Chip, a #NAM platform!    3 key features:  🔹 Resembles brain circuits and neuronal connections  🔹 Combines up to 3 human cell types in 3 interconnected microfluidic chambers  🔹Axon-oriented microchannels    This miniaturized device has various applications:  🔹High Throughput Screening  🔹Drug Testing  🔹Neurotoxicology Studies  🔹Neuronal Connectivity Studies  🔹Neurodevelopmental Studies    🔎Evaluate which fits best your needs and contact us for more information or visit booth 9 at #ESTIV2024 - European Society of Toxicology in Vitro ESTIV.     A platform developed in collaboration with Institute for Bioengineering of Catalonia (IBEC). #3Rs #OrganOnAChip #DrugDiscovery #experimentaltoxicology #innovation #invitro #hPSC #ESTIV24 #Creatio #UniBarcelona #research #brain 

Heading to SOT? Interested in discussing iPSCs, cardiotox and neurotox? Make sure to keep 12pm MDT on Tuesday 12th free in your diary! From the 10th to 14th March, we'll be in Salt Lake City for the Society of Toxicology 63rd Annual Meeting, discussing our work unlocking human iPSC technology for neuro and cardiac safety pharmacology. At 12pm MDT on Tuesday 12th March, we'll be joined by our friends from @innoVitro GmbH to our booth (#2032) to discuss iPSC technology, functional QC, and how we're helping researchers to build better in vitro cardiotoxicity models. You can also hear about our collaborative project with innoVitro testing the chamber-specific pharmacological responses of axoCells atrial and ventricular cardiomyocytes on the FLEXcyte 96 contractility system. Visit ToxExpo Exhibit Hall C on Wednesday 13th March to see poster number P544: "Contractility-based pharmacological characterization of hiPSC-derived atrial and ventricular cardiomyocytes for preclinical toxicity testing". If you're attending SOT, make sure to join us for an informal chat, and for your opportunity to ask any questions about how Axol Bioscience and innoVitro can help you to unlock the benefits of iPSC technology. #SOT #iPSCs #CiPA #cardiotoxicity #neurotoxicity #DrugDiscovery

Heading to SOT? Interested in discussing iPSCs, cardiotox and neurotox? Make sure to keep 12pm MDT on Tuesday 12th free in your diary! From the 10th to 14th March, we'll be in Salt Lake City for the Society of Toxicology 63rd Annual Meeting, discussing our work unlocking human iPSC technology for neuro and cardiac safety pharmacology. At 12pm MDT on Tuesday 12th March, we'll be joined by our friends from innoVitro to our booth (#2032) to discuss iPSC technology, functional QC, and how we're helping researchers to build better in vitro cardiotoxicity models. You can also hear about our collaborative project with innoVitro testing the chamber-specific pharmacological responses of axoCells atrial and ventricular cardiomyocytes on the FLEXcyte 96 contractility system. Visit ToxExpo Exhibit Hall C on Wednesday 13th March to see poster number P544: "Contractility-based pharmacological characterization of hiPSC-derived atrial and ventricular cardiomyocytes for preclinical toxicity testing". If you're attending SOT, make sure to join us for an informal chat, and for your opportunity to ask any questions about how Axol Bioscience and innoVitro can help you to unlock the benefits of iPSC technology. #SOT #iPSCs #CiPA #cardiotoxicity #neurotoxicity #DrugDiscovery

For many labs, it can be a challenge to transition to primary human cells. Join us on Jan. 11 to learn more about why you should consider it anyway. "There are many instances where the extra effort is worth it in terms of improving the translational value," said Sharon Presnell, PhD, LifeNet Health LifeSciences Vice President of Product Development. "During the webinar, I will be covering a case study with human primary thyrocytes that highlights these benefits, through the lens of a toxicology lab." Sign up for Cell Selection for In Vitro Applications: Maximizing Translational Success. https://lnkd.in/dT7akRU

🔬 Maximizing Research Impact: Harnessing the Power of Primary Human Cells! 🔬 In the world of research, precision matters. 🌐 When it comes to unlocking the full potential of our compounds, the choice of cellular models is pivotal. 🧪 🔍 Why Primary Human Cells? 1️⃣ Physiological Relevance: Primary human cells closely mimic in vivo conditions, offering a more authentic representation of cellular responses. 2️⃣ Accurate Predictions: Achieve greater predictability in drug responses, ensuring that findings translate effectively from the lab to real-world applications. 3️⃣ Biomimicry Advantage: Leverage the intricate cellular microenvironment for a deeper understanding of compound interactions, optimizing research outcomes. 4️⃣ Reduced Variability: Minimize experimental variables with cells directly sourced from human tissues, enhancing the reproducibility and reliability of your studies. 💡 Elevate Your Research! By incorporating primary human cells, we're not just advancing science; we're pioneering a new era of precision and relevance in our investigations. Let's push the boundaries of discovery together! 🚀 #ResearchInnovation #PrecisionMedicine #ScientificAdvancements #PrimaryHumanCells #DrugDiscovery #ThyrocyteResearch #RelevantInVitro 🔗 Connect with us to explore how primary human cells can amplify the impact of your research! 🤝 #Networking #ScienceCollaboration #ConnectWithUs